Leopold, Wilbur R.
Pfizer (United States)
3 papers on CoChat
Most cited papers
- Verified
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics
Cancer-related Molecular PathwaysAdvanced Breast Cancer Therapies
Cited by 1,236
- Verified
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 806
- Verified
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters
Melanoma and MAPK PathwaysHeterocyclic Compound Synthesis and Bioactivity
Cited by 289
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free